ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR

臺大醫院;臺大醫院-肝炎研究中心;臺大醫學院;臺大醫學院-臨床醫學研究所;Alberti, A.A.AlbertiChuang, W. -L.W. -L.ChuangFlisiak, R.R.FlisiakMazzella, G.G.MazzellaHorban, A.A.HorbanGoeser, T.T.GoeserCalistru, P.P.CalistruButi, M.M.ButiDavis, G.G.DavisGong, Y.Y.GongAvila, C.C.AvilaKao, J. -H.J. -H.Kao高嘉宏2017-06-222018-07-062017-06-222018-07-062012http://ntur.lib.ntu.edu.tw//handle/246246/279474ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR